Cipla net profit rises 7 percent to Rs 808 crore in Q3
New Delhi: Drug major Cipla on Wednesday reported a 7 percent increase in its consolidated net profit to Rs 808 crore for the third quarter ended December 2022, aided by robust sales.
The Mumbai-based drug maker had reported a net profit of Rs 757 crore for the October-December period of the last fiscal.
Its total revenue from operations rose to Rs 5,810 crore for the third quarter compared to Rs 5,479 in the year-ago period, Cipla said in a regulatory filing.
For the nine months ended December 31, 2022, the company reported a net profit of Rs 2,311 crore against Rs 2,176 crore in the same period last fiscal.
Read also: Cipla expects elevated capital expenditure on automation to continue for three more years
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd